Cargando…

Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records

PURPOSE: To describe attrition patterns of opioid use disorder (OUD) patients treated with buprenorphine (BUP) and to assess how clinical, sociodemographic, or BUP medication dosing features are associated with attrition. PATIENTS AND METHODS: Electronic health records of adults (16+ year-olds) with...

Descripción completa

Detalles Bibliográficos
Autores principales: Ker, Sheryl, Hsu, Jennifer, Balani, Anisha, Mukherjee, Sankha Subhra, Rush, A John, Khan, Mehreen, Elchehabi, Sara, Huffhines, Seth, DeMoss, Dustin, Rentería, Miguel E, Sarkar, Joydeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560173/
https://www.ncbi.nlm.nih.gov/pubmed/34737569
http://dx.doi.org/10.2147/NDT.S331442
_version_ 1784592887546118144
author Ker, Sheryl
Hsu, Jennifer
Balani, Anisha
Mukherjee, Sankha Subhra
Rush, A John
Khan, Mehreen
Elchehabi, Sara
Huffhines, Seth
DeMoss, Dustin
Rentería, Miguel E
Sarkar, Joydeep
author_facet Ker, Sheryl
Hsu, Jennifer
Balani, Anisha
Mukherjee, Sankha Subhra
Rush, A John
Khan, Mehreen
Elchehabi, Sara
Huffhines, Seth
DeMoss, Dustin
Rentería, Miguel E
Sarkar, Joydeep
author_sort Ker, Sheryl
collection PubMed
description PURPOSE: To describe attrition patterns of opioid use disorder (OUD) patients treated with buprenorphine (BUP) and to assess how clinical, sociodemographic, or BUP medication dosing features are associated with attrition. PATIENTS AND METHODS: Electronic health records of adults (16+ year-olds) with OUD treated with BUP from 23 different substance use or mental health care programs across 11 US states were examined for one year following BUP initiation in inpatient (IP), intensive outpatient (IOP), or outpatient (OP) settings. Treatment attrition was declared at >37 days following the last recorded visit. Survival analyses and predictive modelling were used. RESULTS: Retention was consistently 2–3 times higher following BUP initiation in OP (n = 2409) than in IP/IOP (n = 2749) settings after 2 (50% vs 25%), 6 (27% vs 9%) and 12 months (14% vs 4%). Retention was higher for females, whites (vs blacks), and those with less severe OUD, better global function, or not using non-psychotropic medications. Comorbid substance use, other psychiatric disorders, and the number of psychotropic medications were variously related to retention depending on the setting in which BUP was initiated. Predictive modelling revealed that a higher global assessment of functioning and a smaller OUD severity based on the Clinical Global Impression – Severity led to longer retentions, a higher initial BUP dose led to higher retention in a few cases, an OP setting of BUP initiation led to longer retentions, and a lower total number of psychotropic and non-psychotropic medications led to longer retentions. These were the most important parameters in the model, which identified 75.2% of patients who left BUP treatment within three months post-initiation, with a precision of 90.5%. CONCLUSION: Of all the OUD patients who began BUP, 50–75% left treatment within three months, and most could be accurately identified. This could facilitate patient-centered management to better retain OUD patients in BUP treatment.
format Online
Article
Text
id pubmed-8560173
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-85601732021-11-03 Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records Ker, Sheryl Hsu, Jennifer Balani, Anisha Mukherjee, Sankha Subhra Rush, A John Khan, Mehreen Elchehabi, Sara Huffhines, Seth DeMoss, Dustin Rentería, Miguel E Sarkar, Joydeep Neuropsychiatr Dis Treat Original Research PURPOSE: To describe attrition patterns of opioid use disorder (OUD) patients treated with buprenorphine (BUP) and to assess how clinical, sociodemographic, or BUP medication dosing features are associated with attrition. PATIENTS AND METHODS: Electronic health records of adults (16+ year-olds) with OUD treated with BUP from 23 different substance use or mental health care programs across 11 US states were examined for one year following BUP initiation in inpatient (IP), intensive outpatient (IOP), or outpatient (OP) settings. Treatment attrition was declared at >37 days following the last recorded visit. Survival analyses and predictive modelling were used. RESULTS: Retention was consistently 2–3 times higher following BUP initiation in OP (n = 2409) than in IP/IOP (n = 2749) settings after 2 (50% vs 25%), 6 (27% vs 9%) and 12 months (14% vs 4%). Retention was higher for females, whites (vs blacks), and those with less severe OUD, better global function, or not using non-psychotropic medications. Comorbid substance use, other psychiatric disorders, and the number of psychotropic medications were variously related to retention depending on the setting in which BUP was initiated. Predictive modelling revealed that a higher global assessment of functioning and a smaller OUD severity based on the Clinical Global Impression – Severity led to longer retentions, a higher initial BUP dose led to higher retention in a few cases, an OP setting of BUP initiation led to longer retentions, and a lower total number of psychotropic and non-psychotropic medications led to longer retentions. These were the most important parameters in the model, which identified 75.2% of patients who left BUP treatment within three months post-initiation, with a precision of 90.5%. CONCLUSION: Of all the OUD patients who began BUP, 50–75% left treatment within three months, and most could be accurately identified. This could facilitate patient-centered management to better retain OUD patients in BUP treatment. Dove 2021-10-28 /pmc/articles/PMC8560173/ /pubmed/34737569 http://dx.doi.org/10.2147/NDT.S331442 Text en © 2021 Ker et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Ker, Sheryl
Hsu, Jennifer
Balani, Anisha
Mukherjee, Sankha Subhra
Rush, A John
Khan, Mehreen
Elchehabi, Sara
Huffhines, Seth
DeMoss, Dustin
Rentería, Miguel E
Sarkar, Joydeep
Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records
title Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records
title_full Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records
title_fullStr Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records
title_full_unstemmed Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records
title_short Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records
title_sort factors that affect patient attrition in buprenorphine treatment for opioid use disorder: a retrospective real-world study using electronic health records
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560173/
https://www.ncbi.nlm.nih.gov/pubmed/34737569
http://dx.doi.org/10.2147/NDT.S331442
work_keys_str_mv AT kersheryl factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords
AT hsujennifer factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords
AT balanianisha factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords
AT mukherjeesankhasubhra factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords
AT rushajohn factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords
AT khanmehreen factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords
AT elchehabisara factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords
AT huffhinesseth factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords
AT demossdustin factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords
AT renteriamiguele factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords
AT sarkarjoydeep factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords